Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milvexian - Bristol-Myers Squibb/Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Milvexian - Bristol-Myers Squibb/Johnson & Johnson Innovative Medicine

Alternative Names: BMS 177; BMS-986177; JNJ-3093; JNJ-70033093

Latest Information Update: 21 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Johnson & Johnson Innovative Medicine
  • Class Antiarrhythmics; Antithrombotics; Aza compounds; Cardiovascular therapies; Chlorobenzenes; Fluorine compounds; Macrocyclic compounds; Pyrimidinones; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; Atrial fibrillation; Stroke
  • Discontinued Venous thromboembolism

Most Recent Events

  • 08 Sep 2024 Pharmacokinetics, pharmacodynamics and adverse event data from a phase I trial in healthy volunteers presented at the American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
  • 30 Aug 2024 Pharmacokinetics and pharmacodynamics data from the AXIOMATIC-TKR phase II trial in Venous thromboembolism presented at the annual congress of the European Society of Cardiology (ESC-Card-2024)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Stroke(In volunteers) in United Kingdom (PO, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top